Metabolic syndrome (MetS) is a multifaceted disorder that impacts approximately 20–25% of the global population. This syndrome encompasses a range of conditions, including obesity, type 2 diabetes ...

March 20, 2026 PDUFA goal date for sNDA for setmelanotide in acquired hypothalamic obesity -- BOSTON, March 01, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global ...

Researchers discover a gut-brain-heart axis where the bacterial metabolite IAA regulates hypocretin neurons to control heart stiffness and blood pressure.

Central hypothyroidism is a rare disorder that occurs when an otherwise healthy thyroid doesn't produce enough hormone due to problems that originate in the pituitary gland, the hypothalamus, or both.

Before GLP-1 agonists became the blockbuster obesity drugs many people know and use today, Rhythm Pharmaceuticals was researching molecules that take a similar approach but for a different target. The ...